Estradiol/trimegestone transdermal patch - ProStrakan

Drug Profile

Estradiol/trimegestone transdermal patch - ProStrakan

Alternative Names: PSK 3987; Trim patch; Trimegestone/estradiol transdermal patch - ProStrakan

Latest Information Update: 17 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProStrakan; sanofi-aventis
  • Developer ProStrakan
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnadienes
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 19 Apr 2006 Clinical development is ongoing
  • 11 Oct 2005 PSK 3987 is available for licensing (
  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top